Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
EASD 25: EMPIRE-PREVENT: Metabolic Effects of Empagliflozin in Patients at Risk of Heart Failure
Author(s): Camilla Andersen Added: 8 months ago
EASD Congress 2025 - Dr Camilla Andersen (The University of Western Australia, Perth, AU) joins us to discuss findings from the EMPIRE-PREVENT: Metabolic study, investigating the metabolic effects of empagliflozin in elderly and obese patients at high risk of developing heart failure (HF).This randomized controlled trial evaluated 165 patients aged 60–84 years with obesity (BMI >28kg/m²) and… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Management of Hyperkalaemia in Patients with Cardiorenal Disease
Author(s): Antonio Méndez-Durán , Juan B Ivey-Miranda , Genaro H Mendoza-Zavala , et al Added: 1 month ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
AHA 25 Late-breaking Discussion: Analysis from the SURPASS-CVOT Trial
Author(s): Harriette Van Spall , Stephen Nicholls Added: 7 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Stephen Nicholls (Monash University, AU) to present the findings of this AHA late-breaking trial.This pre-specified analysis of the SURPASS-CVOT randomised clinical trial evaluates the comparative effects of once-weekly tirzepatide versus dulaglutide on heart failure outcomes in… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
The Global Obesity Epidemic
Author(s): Alex E Henney , John PH Wilding Added: 2 weeks ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Metabolic Factors Now Key Drivers of Heart Failure
Added: 5 months ago Source:  Radcliffe Cardiology
The primary drivers of heart failure (HF) have shifted significantly over the past 35 years, with metabolic conditions such as obesity and diabetes now playing a more prominent role than traditional risk factors like myocardial infarction (MI).¹˒² This finding comes from a large US-based study analysing national health trends.MethodologyResearchers conducted a retrospective analysis of data from… View more

MI/ACS

Prevention & Chronic Conditions
Obesity in Focus: Implications for Heart Failure, Kidney Disease, and Pharmacology
Author(s): Chim C Lang , Bianca Rocca , Samira Bell Added: 8 months ago
In this short discussion, join Prof Chim Lang (University of Dundee, Dundee, UK), Guest Editor of the upcoming Special Focus on Obesity in Focus, Prof Bianca Rocca (LUM University, Casamassima, IT) and Dr Samira Bell (University of Dundee, Dundee, UK) to discover the implications of obesity on heart failure, kidney disease, and pharmacology.This conversation sets the stage for the upcoming… View more

Cardiovascular Kidney Metabolic

Heart Failure
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 1 year ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Kidney Metabolic

Heart Failure
HFA 24: FINE-HEART: Design & Baseline Characteristics
Author(s): Muthiah Vaduganathan Added: 2 years ago
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the design and baseline characteristics of the FINE-HEART(Bayer) integrated pooled analysis of finerenone, an on-steroidal mineralocorticoid receptor (MRA) antagonist, in over 19000 patients with heart failure and CKD.FINE-HEART includes patients with type 2 diabetes, chronic kidney disease and/or… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Obesity, Cardiac MRI Structure and Non-ischaemic Cardiomyopathy
Author(s): Long Peng , Tao Zeng , Enxi Quan , et al Added: 1 year ago

Cardiovascular Kidney Metabolic

Heart Failure
HFA 24 Late-Breaker Discussion: The TITRATE-HF Study
Author(s): Jasper J Brugts , Harriette Van Spall Added: 2 years ago
HFA 24 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined onsite by Dr Jasper Brugts (Erasmus University Medical Centre, NL) to discuss the first results from the TITRATE-HF study.TITRATE-HF is a real-world multicenter longitudinal study which aims to assess drug sequencing strategies for guideline-directed medical therapy (GDMT) initiation in patients with de novo,… View more

Heart Failure